Join us in March 2022 to experience 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
With over 100+ attendees, learn how new technologies and innovative processes are fundamentally changing what the drug discovery research will look like in the next two to five years.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on the adoption of technology to combat these.
ROAD TO AI
LEAD GENERATION STRATEGIES
ADVANCES IN DRUG DESIGN
RNA THERAPEUTICS ON THE RISE
SMALL MOLECULES IN DRUG DISCOVERY
TRANSLATING OMICS INTO THERAPEUTICS
PRECLINICAL STRATEGIES, MODELS AND TOOLS
COLLABORATE TO ACCELERATE
HIT TRIAGE AND VALIDATION STRATEGIES
MEDICINAL CHEMISTRY TOOLBOX
NOVEL DRUG TARGET DISCOVERY & VALIDATION
Meet our professonals
Senior Research Fellow, Computational Chemistry
President & Chief Executive Officer
Associate professor of Medicine
University of Montpellier
Leader of Pre-Clinical and Clinical Research, PM
Duchenne Parent Project Spain
Professor of Biochemistry and Structural Biology
University of Oxford, Nuffield Department of Medicine
Associate Director, Protein Engineering & Antibody Technologies
Head of Therapeutic Area Immuno-Inflammation, Application of AI to Drug Development
SAI LIFE SCIENCES LTD
what people say
Domainex is an award-winning integrated drug discovery research service partner, providing the full range of pre-clinical drug discovery services. They work collaboratively in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. their team comprises of approximately 70 scientists, who are committed to providing high quality services, and have expertise in:
Domainex has also established innovative technology platforms enabling us to offer unique services including:
Combinatorial Domain Hunting: our patented technology to quickly identify soluble, highly expressed domain constructs of proteins by combining semi-random gene fragmentation with efficient screening of the resulting protein fragments.
see what we did lately